Paradigm Biopharmaceuticals (ASX:PAR) receives FDA feedback

Retrieved on: 2021-05-24 23:37:30

Tags for this article:

Click the tags to see associated articles and topics

Paradigm Biopharmaceuticals (ASX:PAR) receives FDA feedback. View article details on hiswai:

Excerpt

Paradigm Biopharmaceuticals (PAR) has received written feedback regarding its investigational new drug submission for a study evaluating knee ...

Article found on: themarketherald.com.au